Medication info
Olmesartan Medoxomil Hydrochlorothiazide Plus Tablet

Olmesartan Medoxomil Hydrochlorothiazide Plus Tablet

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Ilhwa Co., Ltd.
Appearance
Round film-coated tablet with yellowish color
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201100911 · Approved 2011.02.24 · Insurance code 640902310

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Before administering this medicine, it is recommended that the doses of olmesartan medoxomil or hydrochlorothiazide be adjusted separately. If blood pressure is not adequately controlled with the individual components, administer 1 tablet of this medicine once daily, with or without food. The dose should be adjusted at intervals of 2~4 weeks, taking the patient's blood pressure response into account. A marked blood pressure-lowering effect may occur when olmesartan medoxomil is added or when patients taking a high dose of hydrochlorothiazide as a single agent, or patients with volume depletion or hyponatremia, are switched to this medicine (olmesartan medoxomil/hydrochlorothiazide). In such cases, the dose of hydrochlorothiazide should be reduced to 12.5mg before adding olmesartan medoxomil. <Elderly patients> In elderly patients, start at the lowest dose and use caution when adjusting the dose, taking into account the patient's renal or cardiac function, comorbidities, and other concomitant medications. <Patients with renal impairment> This medicine (olmesartan medoxomil/hydrochlorothiazide) is generally administered to patients with mild to moderate renal impairment (creatinine clearance>30mL/min). This medicine (olmesartan medoxomil/hydrochlorothiazide) should not be administered to patients with more severe renal impairment, as loop diuretics are preferable to thiazide diuretics in these patients. <Patients with hepatic impairment> Use of this medicine is not recommended in patients with hepatic impairment because there is no experience with its use in these patients.
Child dose
<Children> Safety and efficacy in children have not been established.

Ingredients

Manufacturer
Ilhwa Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used in patients with essential hypertension whose blood pressure control is insufficient with Olmesartan Medoxomil or Hydrochlorothiazide alone. It effectively lowers blood pressure and helps reduce the risk of cardiovascular complications.

How to take

Adult dose

Before administering this medicine, it is recommended that the doses of olmesartan medoxomil or hydrochlorothiazide be adjusted separately. If blood pressure is not adequately controlled with the individual components, administer 1 tablet of this medicine once daily, with or without food. The dose should be adjusted at intervals of 2~4 weeks, taking the patient's blood pressure response into account. A marked blood pressure-lowering effect may occur when olmesartan medoxomil is added or when patients taking a high dose of hydrochlorothiazide as a single agent, or patients with volume depletion or hyponatremia, are switched to this medicine (olmesartan medoxomil/hydrochlorothiazide). In such cases, the dose of hydrochlorothiazide should be reduced to 12.5mg before adding olmesartan medoxomil. <Elderly patients> In elderly patients, start at the lowest dose and use caution when adjusting the dose, taking into account the patient's renal or cardiac function, comorbidities, and other concomitant medications. <Patients with renal impairment> This medicine (olmesartan medoxomil/hydrochlorothiazide) is generally administered to patients with mild to moderate renal impairment (creatinine clearance>30mL/min). This medicine (olmesartan medoxomil/hydrochlorothiazide) should not be administered to patients with more severe renal impairment, as loop diuretics are preferable to thiazide diuretics in these patients. <Patients with hepatic impairment> Use of this medicine is not recommended in patients with hepatic impairment because there is no experience with its use in these patients.

Child dose

<Children> Safety and efficacy in children have not been established.

Precautions

This medication may cause serious harm or death to the fetus or newborn if taken during the second and third trimesters of pregnancy, therefore it should be discontinued immediately upon confirmation of pregnancy. It should not be used in patients with allergies to this drug or its components, specific kidney or liver diseases, or in women who are pregnant or breastfeeding. Patients with significantly low blood pressure, severely impaired kidney function, and certain electrolyte abnormalities should use this medication with caution, and their conditions should be closely monitored before and during treatment. As this medication lowers blood pressure, dizziness or symptoms of hypotension may occur when starting treatment, and appropriate actions should be taken if symptoms arise. It can affect kidney function; therefore, patients with impaired kidney function should have regular blood tests to check kidney status. Patients with severely impaired liver function or certain heart diseases also require caution, and electrolyte imbalances or dehydration should be managed. This medication may increase the risk of skin cancer; therefore, sun exposure should be minimized, and any skin abnormalities should be immediately consulted with a doctor. During treatment, symptoms such as dizziness, headache, indigestion, muscle pain, rash, and others may occur, and if there are severe edema or breathing difficulties, healthcare personnel should be informed immediately. This medication can interact with other drugs; therefore, especially if taking potassium supplements, diuretics, lithium, or anti-inflammatory drugs, it is essential to inform healthcare personnel and be cautious. Pregnant and breastfeeding women should pay special attention to taking this medication, and breastfeeding should be avoided or paused while taking this medication. In children and the elderly, the safety and efficacy of this medication have not been well established, or there may be impaired kidney function, so dosage adjustments and caution are necessary. In cases of overdose, symptoms such as hypotension, electrolyte imbalance, and dehydration may occur, and appropriate treatment should be received at a medical institution immediately. Regular blood tests and monitoring of electrolytes, kidney function, and liver function during medication use are important.

Side effects

nausea, hyperuricemia, dizziness, upper respiratory tract infection, headache, urinary tract infection, chest pain, back pain, peripheral edema, vertigo, abdominal pain, dyspepsia, gastroenteritis, diarrhea, elevated AST, elevated GGT, elevated ALT, hyperlipidemia, elevated creatine phosphokinase, hyperglycemia, arthritis, arthralgia, myalgia, cough, rash, hematuria, facial edema, weakness, angioedema, anaphylactic reaction, vomiting, hair loss, pruritus, urticaria, hyponatremia, frequent urination, palpitations, hypercholesterolemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis, sinusitis, headache, fatigue, drowsiness, emotional blunting, restlessness, interstitial pneumonia, pulmonary edema, acute respiratory distress syndrome, orthostatic hypotension, arrhythmia, transient blurred vision, jaundice, choroidal effusion, jaundice, hepatitis, acute cholecystitis, necrotizing vasculitis, vasculitis, cutaneous vasculitis, dyspnea, malaise, nasal congestion, erectile dysfunction, systemic lupus erythematosus exacerbation, parathyroid gland disorder, muscle cramps, sensory abnormalities, frailty, Stevens-Johnson syndrome, erythema multiforme, exfoliative dermatitis, toxic epidermal necrolysis, hypokalemia, hypomagnesemia, hypochloremic alkalosis, hypercalcemia, thrombocytopenia, leukopenia, aplastic anemia, hemolytic anemia, purpura, loss of appetite, thirst, abdominal discomfort, constipation, abdominal colic, pancreatitis, jaundice, sialadenitis, dry mouth, abnormal liver function tests, chronic malabsorption syndrome-like intestinal disorder, intestinal vascular edema, rhabdomyolysis, acute renal failure, increased blood creatinine, elevated blood pressure, epistaxis, asthma, elevated blood creatinine, autoimmune hepatitis, hypotension due to blood pressure lowering, palpitations, bradycardia, nausea, drowsiness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is advisable to maintain a storage temperature between 1°C and 25°C. By storing it this way, the effectiveness and safety of the medication can be maintained for a long time.

Appearance and packaging

Appearance

Round film-coated tablet with yellowish color

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.